



**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123  
 Regd. Office: Alembic Road, Vadodara - 390 003  
 Tel: +91 265 2280550  
 Email: apl.investors@alembic.co.in  
 Website: www.alembicpharmaceuticals.com

**Extract of Statement of Consolidated Audited Financial Results  
 for the quarter and financial year ended 31<sup>st</sup> March, 2023**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2023	31.03.2022	31.03.2023
	Audited	Audited	Audited
Total Income from Operations	1,406.45	1,415.74	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	116.17	28.66	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	116.17	28.66	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	152.60	21.92	341.99
Total Comprehensive Income for the period	151.42	22.14	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	7.76	1.11	17.40
Research and Development Expenses	136.25	349.80	721.84

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2023	31.03.2022	31.03.2023
	Audited	Audited	Audited
Income from Operations	1,307.12	1,317.67	5,149.00
Profit Before Tax	84.01	49.65	345.93
Profit After Tax	130.54	41.52	346.73
Research and Development Expenses	135.49	346.29	699.39

2. The above is an extract of the detailed format of the Audited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin  
 Chairman & CEO

Place: London  
 Date: 5<sup>th</sup> May, 2023